| Title |
Risperidone versus other atypical antipsychotics for schizophrenia
|
|---|---|
| Published in |
Cochrane database of systematic reviews, January 2011
|
| DOI | 10.1002/14651858.cd006626.pub2 |
| Pubmed ID | |
| Authors |
Katja Komossa, Christine Rummel‐Kluge, Sandra Schwarz, Franziska Schmid, Heike Hunger, Werner Kissling, Stefan Leucht |
| Abstract |
In many countries of the industrialised world second-generation ("atypical") antipsychotics (SGAs) have become the first line drug treatment for people with schizophrenia. The question as to whether and if so how much the effects of the various SGAs differ is a matter of debate. In this review we examined how the efficacy and tolerability of risperidone differs from that of other SGAs. |
X Demographics
The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 29% |
| Turkey | 1 | 14% |
| Unknown | 4 | 57% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 86% |
| Practitioners (doctors, other healthcare professionals) | 1 | 14% |
Mendeley readers
The data shown below were compiled from readership statistics for 289 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 2 | <1% |
| Chile | 1 | <1% |
| Uruguay | 1 | <1% |
| Brazil | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 283 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 47 | 16% |
| Researcher | 36 | 12% |
| Student > Bachelor | 32 | 11% |
| Student > Ph. D. Student | 26 | 9% |
| Other | 18 | 6% |
| Other | 48 | 17% |
| Unknown | 82 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 88 | 30% |
| Psychology | 25 | 9% |
| Nursing and Health Professions | 20 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 16 | 6% |
| Neuroscience | 11 | 4% |
| Other | 34 | 12% |
| Unknown | 95 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 20. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 May 2023.
All research outputs
#1,896,261
of 25,959,914 outputs
Outputs from Cochrane database of systematic reviews
#4,048
of 13,168 outputs
Outputs of similar age
#10,294
of 199,716 outputs
Outputs of similar age from Cochrane database of systematic reviews
#28
of 120 outputs
Altmetric has tracked 25,959,914 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,168 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.8. This one has gotten more attention than average, scoring higher than 69% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 199,716 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 120 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.